These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38181795)

  • 1. A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
    Zhou C; Hu Y; Arkania E; Kilickap S; Ying K; Xu F; Wu L; Wang X; Viguro M; Makharadze T; Sun H; Luo F; Shi J; Zang A; Pan Y; Chen Z; Jia Z; Kuchava V; Lu P; Zhang L; Cheng Y; Kang W; Wang Q; Yu H; Li J; Zhu J;
    Cancer Cell; 2024 Feb; 42(2):198-208.e3. PubMed ID: 38181795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
    Cheng Y; Han L; Wu L; Chen J; Sun H; Wen G; Ji Y; Dvorkin M; Shi J; Pan Z; Shi J; Wang X; Bai Y; Melkadze T; Pan Y; Min X; Viguro M; Li X; Zhao Y; Yang J; Makharadze T; Arkania E; Kang W; Wang Q; Zhu J;
    JAMA; 2022 Sep; 328(12):1223-1232. PubMed ID: 36166026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.
    Zhou C; Wang Z; Sun Y; Cao L; Ma Z; Wu R; Yu Y; Yao W; Chang J; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Wang J; Li P; Qin M; Lu D; Yang J
    Lancet Oncol; 2022 Feb; 23(2):220-233. PubMed ID: 35038432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
    Song Y; Zhang B; Xin D; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Li J; Wang Q; Zhu J; Huang J;
    Nat Med; 2023 Feb; 29(2):473-482. PubMed ID: 36732627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N
    JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
    Spigel DR; Luft A; Depenbrock H; Ramlau R; Khalil M; Kim JH; Mayo C; Chao GY; Obasaju C; Natale R
    Clin Lung Cancer; 2017 Sep; 18(5):480-488. PubMed ID: 28365238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.
    Govindan R; Szczesna A; Ahn MJ; Schneider CP; Gonzalez Mella PF; Barlesi F; Han B; Ganea DE; Von Pawel J; Vladimirov V; Fadeeva N; Lee KH; Kurata T; Zhang L; Tamura T; Postmus PE; Jassem J; O'Byrne K; Kopit J; Li M; Tschaika M; Reck M
    J Clin Oncol; 2017 Oct; 35(30):3449-3457. PubMed ID: 28854067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
    Liu S; Jiang N; Dou L; Li S
    Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
    Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
    Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
    Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A
    Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
    Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
    Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and Design of a Phase II Trial of Combined Serplulimab and Chemotherapy in Patients with Histologically Transformed Small Cell Lung Cancer: a Prospective, Single-arm and Multicentre Study.
    Huang J; Zhang XH; Cai Y; Yang D; Shi J; Xing P; Xu T; Wu L; Su W; Xu R; Wei T; Chen HJ; Yang JJ
    Clin Oncol (R Coll Radiol); 2024 Jan; 36(1):39-45. PubMed ID: 37977903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
    Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
    Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-inventing a better wheel? Serplulimab for squamous cell lung cancer.
    Huang DD; Yang JC
    Cancer Cell; 2024 Feb; 42(2):172-174. PubMed ID: 38350419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial.
    Jotte R; Cappuzzo F; Vynnychenko I; Stroyakovskiy D; Rodríguez-Abreu D; Hussein M; Soo R; Conter HJ; Kozuki T; Huang KC; Graupner V; Sun SW; Hoang T; Jessop H; McCleland M; Ballinger M; Sandler A; Socinski MA
    J Thorac Oncol; 2020 Aug; 15(8):1351-1360. PubMed ID: 32302702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.